Anoikis-Related Gene Signature for Triple-Negative Breast Cancer Prognosis

A six-gene prognostic signature stratifies triple-negative breast cancer patients into high- and low-risk groups with a significant difference in overall survival. The dataset, authored by Yan Chen and last updated in May 2026, likely contains results from Cox regression and random survival forest analyses used to construct the signature and identify CCAR2 as a key gene. It includes associations with the immunogenomic landscape and predictions for targeted therapy and immunotherapy response.

Use Cases

• Predicting patient prognosis based on the six-gene anoikis-related signature.
• Assessing potential immunotherapy response based on correlations with the immunogenomic landscape.
• Identifying key driver genes like CCAR2 for further functional validation in metastasis studies.
• Building clinical nomograms for risk stratification using the described prognostic signatures.

Strengths

• Signature is based on a defined set of six anoikis-related genes.
• Analysis includes validation via RT-qPCR, immunohistochemistry, and in vitro functional experiments for the key gene CCAR2.
• The clinical nomogram is described as achieving good calibration and strong discriminatory accuracy.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (673.0 KB), indicating limited raw data scope.

Provenance

Source

figshare, author Yan Chen.

Collection Method

Likely contains results from bioinformatics analyses (Cox regression, random survival forest) and experimental validation (RT-qPCR, immunohistochemistry, in vitro assays).

Freshness

Last updated 2026-05-20 05:47:37; freshness should be verified.